{"url_path":"/sec/lfwd/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBIT INDEX","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1607962/0001178913-26-002862-index.html","accession_number":"0001178913-26-002862","cik":"0001607962","ticker":"LFWD","issuer_name":"Lifeward Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1607962/0001178913-26-002862-index.html","primary_entity_key":"0001607962","primary_entity_name":"Lifeward Ltd."},"word_count":550,"has_tables":true,"body_markdown":"ITEM 6. EXHIBIT INDEX  \n\n \n\n**Exhibit**\n\n**Number**\n\n \n**Description**\n\n[2.1](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_2-1.htm)\n \n[Share Purchase Agreement, dated January 12, 2026 among Lifeward, Ltd., Oramed Pharmaceuticals, Inc. and Oratech Pharma, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_2-1.htm)\n\n[2.2](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/exhibit_2-1.htm)\n \n[First Amendment to Share Purchase Agreement, dated March 25, 2026, by and among Lifeward Ltd., Oramed Pharmaceuticals, Inc. and Oratech Pharma Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on Maech 25, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/exhibit_2-1.htm)\n\n[2.3](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/exhibit_2-2.htm)\n \n[Assignment and Assumption Agreement, dated March 25, 2026, by and between Oratech Pharma Inc. and Oratech Ltd. and acknowledged by Lifeward Ltd. (incorporated by reference to Exhibit 2.2 to the Company’s Current Report on Form 8-K filed with the SEC on Maech 25, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326001724/exhibit_2-2.htm)\n\n[4.1](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-1.htm)\n \n[Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-1.htm)\n\n[4.2](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-2.htm)\n \n[Form of Transaction Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-2.htm)\n\n[4.3](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-3.htm)\n \n[Form of Senior Secured Convertible Note (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-3.htm)\n\n[4.4](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-4.htm)\n \n[Form of Common Warrant (incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_4-4.htm)\n\n[10.1](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_10-1.htm)\n \n[Securities Purchase Agreement, dated January 12, 2026, by and among the Company and the investors thereto and Oramed Pharmaceuticals, Inc., as agent (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_10-1.htm)\n\n[10.2](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_10-2.htm)\n \n[Form of Lock-up Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2026).](https://www.sec.gov/Archives/edgar/data/1607962/000117891326000132/exhibit_10-2.htm)\n\n[31.1**](exhibit_31-1.htm)\n \n[Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002.](exhibit_31-1.htm)\n\n[31.2**](exhibit_31-2.htm)\n \n[Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002.](exhibit_31-2.htm)\n\n[32.1*](exhibit_32-1.htm)\n \n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*](exhibit_32-1.htm)\n\n[32.2*](exhibit_32-2.htm)\n \n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*](exhibit_32-2.htm)\n\n101.INS\n \nXBRL Instance Document\n\n101.SCH\n \nXBRL Taxonomy Extension Schema Document\n\n101.PRE\n \nXBRL Taxonomy Extension Presentation Linkbase Document\n\n101.CAL\n \nXBRL Taxonomy Extension Calculation Linkbase Document\n\n101.LAB\n \nXBRL Taxonomy Extension Label Linkbase Document\n\n101.DEF\n \nXBRL Taxonomy Extension Definition Linkbase Document\n\n104\n \nCover Page Interactive Data File – formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.\n\n__________________________\n\n \n\n*\nFurnished herewith.\n\n **\n Filed herewith\n\n^\nPortions of this exhibit (indicated by asterisks) have been omitted under rules of the SEC permitting the confidential treatment of select information.\n\n11\n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n**Lifeward Ltd.**\n\n \n \n\nDate: May 20, 2026\nBy:\n/s/ Mark Grant\n\n \n \nMark Grant\n\n \n \n\nChief Executive Officer\n\n(Principal Executive Officer)\n\n \n \n \n\nDate: May 20, 2026\nBy:\n/s/ Almog Adar\n\n \n \nAlmog Adar\n\n \n \nChief Financial Officer\n\n \n \n(Principal Financial Officer)\n\n \n\n12"}